103.01
전일 마감가:
$102.36
열려 있는:
$102.74
하루 거래량:
1.85M
Relative Volume:
0.23
시가총액:
$147.06B
수익:
$17.55B
순이익/손실:
$2.03B
주가수익비율:
75.19
EPS:
1.37
순현금흐름:
$2.72B
1주 성능:
+1.41%
1개월 성능:
-1.28%
6개월 성능:
+13.28%
1년 성능:
+34.48%
보스턴사이언티픽 Stock (BSX) Company Profile
명칭
Boston Scientific Corp
전화
508-683-4000
주소
300 BOSTON SCIENTIFIC WAY, MARLBOROUGH, MA
BSX을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
![]()
BSX
Boston Scientific Corp
|
103.06 | 147.06B | 17.55B | 2.03B | 2.72B | 1.37 |
![]()
ABT
Abbott Laboratories
|
133.05 | 233.36B | 42.34B | 13.50B | 6.66B | 7.71 |
![]()
SYK
Stryker Corp
|
381.16 | 145.64B | 23.22B | 2.86B | 3.58B | 7.40 |
![]()
MDT
Medtronic Plc
|
85.19 | 112.76B | 33.54B | 4.66B | 5.19B | 3.62 |
![]()
EW
Edwards Lifesciences Corp
|
76.05 | 44.46B | 5.54B | 4.18B | 623.10M | 7.00 |
보스턴사이언티픽 Stock (BSX) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2025-06-16 | 개시 | Leerink Partners | Outperform |
2025-04-16 | 업그레이드 | Needham | Hold → Buy |
2025-01-10 | 업그레이드 | Deutsche Bank | Hold → Buy |
2024-10-18 | 다운그레이드 | Needham | Buy → Hold |
2024-05-30 | 개시 | Goldman | Buy |
2024-02-01 | 업그레이드 | Mizuho | Neutral → Buy |
2023-07-19 | 개시 | Robert W. Baird | Outperform |
2023-06-30 | 개시 | CL King | Buy |
2023-05-30 | 재개 | Morgan Stanley | Overweight |
2023-03-29 | 개시 | UBS | Buy |
2022-12-22 | 개시 | Mizuho | Neutral |
2022-12-20 | 재개 | Citigroup | Buy |
2022-10-18 | 개시 | Barclays | Overweight |
2022-10-12 | 개시 | Jefferies | Buy |
2022-07-06 | 개시 | Wolfe Research | Outperform |
2022-05-27 | 업그레이드 | Needham | Hold → Buy |
2022-04-13 | 재개 | Truist | Buy |
2022-03-02 | 재개 | BofA Securities | Buy |
2021-12-10 | 개시 | RBC Capital Mkts | Outperform |
2021-05-26 | 다운그레이드 | Needham | Buy → Hold |
2021-05-25 | 개시 | Barclays | Overweight |
2021-04-15 | 개시 | Atlantic Equities | Overweight |
2020-09-17 | 개시 | Truist | Buy |
2020-09-11 | 개시 | Wolfe Research | Peer Perform |
2020-04-22 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
2020-04-01 | 업그레이드 | Goldman | Neutral → Buy |
2020-03-05 | 개시 | Citigroup | Buy |
2020-02-13 | 개시 | Goldman | Neutral |
2020-02-06 | 재개 | BTIG Research | Buy |
2019-12-30 | 재확인 | Cowen | Outperform |
2019-12-19 | 다운그레이드 | Needham | Strong Buy → Buy |
2019-09-05 | 재개 | JP Morgan | Overweight |
2019-09-03 | 재개 | Barclays | Overweight |
2019-05-13 | 업그레이드 | Evercore ISI | In-line → Outperform |
2018-11-28 | 개시 | UBS | Buy |
2018-10-16 | 개시 | Barclays | Overweight |
2018-10-02 | 재확인 | Morgan Stanley | Overweight |
2018-09-07 | 재확인 | Needham | Strong Buy |
2018-09-04 | 업그레이드 | Jefferies | Hold → Buy |
2018-07-06 | 재확인 | Needham | Strong Buy |
2018-06-27 | 개시 | Bernstein | Outperform |
2018-04-26 | 재확인 | Needham | Strong Buy |
모두보기
보스턴사이언티픽 주식(BSX)의 최신 뉴스
February 2026 Options Now Available For Boston Scientific (BSX) - Nasdaq
Boston Scientific’s Q1 Earnings Call: Our Top 5 Analyst Questions - Yahoo Finance
Leerink starts coverage on Boston Scientific and Medtronic with bullish ratings - Investing.com Canada
This Boston Scientific Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Benzinga
Boston Scientific (BSX) Receives Outperform Rating from Leerink Partners | BSX Stock News - GuruFocus
Boston Scientific (BSX) Receives Outperform Rating from Analyst | BSX Stock News - GuruFocus
Does This Valuation Of Boston Scientific Corporation (NYSE:BSX) Imply Investors Are Overpaying? - Yahoo Finance
Why the Market Dipped But Boston Scientific (BSX) Gained Today - Yahoo Finance
Boston Scientific Shares Rally Over 1%, Highlighting Strong Long-Term Growth - Daily Chhattisgarh News
BSX Q1 Endoscopy Sales Rise 6%: What's Behind the Growth? - Yahoo Finance
What's the secret behind Boston Sci's successful product launches? - BioWorld MedTech
Implantable Remote Patient Monitoring Devices Market to Grow 21.7% CAGR by 2029 - GlobeNewswire Inc.
Five things: The Newbury GM, Zoominfo cuts, Vertex, Boston Scientific and casino night - The Business Journals
Boston Scientific to sell 24-acre campus in Minnetonka - Finance & Commerce
Boston Scientific is selling a Minnesota campus - MassDevice
Cardiovascular Tailwind Boosts BSX: Here's How to Play the Stock - The Globe and Mail
Boston Scientific lists 24-acre Minnesota campus for sale ahead of Maple Grove move - The Business Journals
How Is Boston Scientific's Stock Performance Compared to Other Medical Device Stocks? - MSN
Boston Scientific lists 24-acre Minnetonka campus for sale ahead of Maple Grove move - The Business Journals
Boston Scientific Stock Slips Over 1% Amid Short-Term Pullback - Daily Chhattisgarh News
Boston Scientific (BSX) Upgraded to Buy: Here's Why - Yahoo Finance
Is Boston Scientific (BSX) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Wall Street Bulls Look Optimistic About Boston Scientific (BSX): Should You Buy? - Yahoo Finance
Boston Scientific’s EVP sells $5.8 million in stock By Investing.com - Investing.com Nigeria
Boston Scientific’s EVP sells $5.8 million in stock - Investing.com
Boston Scientific (BSX) Stock Declines While Market Improves: Some Information for Investors - Yahoo Finance
Boston Scientific (NYSE:BSX) Secures US$30-45 Million Deal with Bittium for ECG Devices - Yahoo Finance
Emerging Markets Power Boston Scientific: Will The Growth Trend Continue? - Barchart.com
Here's Why Boston Scientific (BSX) is a Strong Growth Stock - Yahoo Finance
Emerging Markets Power Boston Scientific: Will the Growth Trend Continue? - Yahoo Finance
How Is Boston Scientific's Stock Performance Compared To Other Medical Device Stocks? - Barchart.com
Rising obesity levels spur endoscopic sleeve uptick - BioWorld MedTech
Boston Scientific (BSX): Company Profile, Stock Price, News, Rankings - Fortune
Boston Scientific’s longtime DEI, HR leader exits for chief HR role at new company - MassDevice
Insider Sell: Edward Ludwig Sells 4,000 Shares of Boston Scienti - GuruFocus
Before the Bell-Boston Scientific drops on profit miss - Reuters
Insider Sell: Edward Ludwig Sells 4,000 Shares of Boston Scientific Corp (BSX) - GuruFocus
Piper Sandler maintains Boston Scientific stock at Overweight - Investing.com
Boston Scientific (NYSE:BSX) Receives “Buy” Rating from Needham & Company LLC - Defense World
Boston Scientific Scraps This Aortic Valve, Sticks To 2025 Outlook - Benzinga
Boston Scientific ends TAVR sales; J&J shares Monarch robot data - MedTech Dive
Boston Scientific (BSX) Ends Acurate TAVR Program, Shifts Focus to Promising Projects | BSX Stock News - GuruFocus
BSX: Analyst Reiterates Buy Rating for Boston Scientific | BSX S - GuruFocus
In TAVR setback, Boston Sci pulls plug on Acurate valves - BioWorld MedTech
Boston Scientific discontinues Acurate TAVR sales, cites regulatory burden - MassDevice
Boston Scientific Ends ACURATE Valve Sales By Investing.com - Investing.com Canada
Evercore ISI maintains Boston Scientific stock at Outperform - Investing.com
TD Cowen maintains Boston Scientific stock at $115 target By Investing.com - Investing.com South Africa
TD Cowen maintains Boston Scientific stock at $115 target - Investing.com
Boston Scientific (BSX) Discontinues Sales of ACURATE Aortic Valve Systems - GuruFocus
Boston Scientific (BSX) Discontinues Valve Product Amid Regulato - GuruFocus
보스턴사이언티픽 (BSX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
보스턴사이언티픽 주식 (BSX) 내부자 거래
내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
---|---|---|---|---|---|---|---|
Fitzgerald Joseph Michael | EVP & Group Pres, Cardiology |
Jun 04 '25 |
Sale |
102.88 |
56,372 |
5,799,630 |
178,342 |
자본화:
|
볼륨(24시간):